Please wait while your page loads ...

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist
Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD)
Potential for seven years of marketing exclusivity in the USA upon approval in the orphan designation indication

Can't see this document? Click Here


Scientific News Archives

Tagged in
Scientific News


Privacy Policy      Service Terms      Contact      Charity Navigator